A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 AllogeneicCRISPR-Cas9???Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies

Project: Research project

Project Details

Description

A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9???Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies
StatusActive
Effective start/end date6/1/20 → 5/31/25

Funding

  • CRISPR THERAPEUTICS, INC

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
View full fingerprint